ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9475
-1.20%
Brent Oil
83.54
-2.74%
Bitcoin
58,202.34
-3.96%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) Noticias

NRSN NeuroSense Therapeutics Ltd

1.26
-0.09 (-6.67%)
Fuera de horario
Última actualización: 17:30:10
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
NeuroSense Therapeutics Ltd NRSN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.09 -6.67% 1.26 17:30:10
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.37 1.24 1.42 1.26 1.35
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
22/4/202407:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
18/4/202407:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
12/4/202407:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
10/4/202418:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
09/4/202407:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
05/4/202408:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
22/2/202407:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202407:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
13/2/202412:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202409:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202408:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/2/202408:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
09/1/202407:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202407:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202407:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
27/12/202316:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/12/202316:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/12/202316:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
21/12/202307:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202315:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/12/202308:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202308:24PRNUSNeuroSense Reports New Data: Statistically Significant..
05/12/202314:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/12/202314:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
05/12/202307:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202307:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
04/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
04/12/202315:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
04/12/202305:17EDGAR2Form POS AM - Post-Effective amendments for registration..
28/11/202308:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202307:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
21/11/202309:36EDGAR2Form POS AM - Post-Effective amendments for registration..
13/11/202308:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202308:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
09/11/202308:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
06/11/202307:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202307:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
01/11/202308:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
17/10/202307:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/10/202307:30PRNUSNeuroSense CEO Provides Q3 2023 Update
04/10/202308:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202308:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
02/10/202310:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202308:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202308:05PRNUSEuropean Medicines Agency Grants NeuroSense SME Status
19/9/202308:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/9/202308:00PRNUSNeuroSense Granted Patents in Europe, Japan, and Israel for..
14/9/202308:00PRNUSNeuroSense to Participate in Upcoming ALS Conferences:..
12/9/202308:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/9/202315:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]

Su Consulta Reciente

NASDAQ
NRSN
NeuroSense Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados